Agreements reached under this partnership
Business Alliances- 1
Under this agreement, we will acquire exclusive rights to develop and market the drug in Japan for the treatment of ARDS.
- 2
We will partner with Edesa Biotech to develop the drug for the treatment of ARDS, and we will be responsible for clinical trials in Japan.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Up to US$134 million in milestone payments, from development through regulatory drug-price listing and the achievement of a specified level of net sales. Timing of achievement: Not disclosed.
The upfront payment of US$12 million will be recorded in selling, general and administrative expenses (R&D expenses) for the third quarter of the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Name of alliance partner | Edesa Biotech, Inc. |
| Alliance partner's business activities | A biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases. Its clinical development pipeline focuses on 2 therapeutic areas: dermatology and respiratory diseases. |
| Alliance partner's location | Toronto, Canada |
| Type of alliance | Business Alliances |
| Details of the alliance | Under this agreement, we will acquire exclusive rights to develop and market the drug in Japan for the treatment of ARDS., We will partner with Edesa Biotech to develop the drug for the treatment of ARDS, and we will be responsible for clinical trials in Japan. |
| Numerical targets under the alliance | Up to US$134 million in milestone payments, from development through regulatory drug-price listing and the achievement of a specified level of net sales. Timing of achievement: Not disclosed. |
| Contract Date | 9 November 2026 |
| Impact on Business Performance | The upfront payment of US$12 million will be recorded in selling, general and administrative expenses (R&D expenses) for the third quarter of the fiscal year ending March 2027. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ARDS is a disease with high unmet medical needs because it has a high mortality rate and limited pharmacological treatment options. The agreement will also advance the expansion of the development pipeline through proactive in-licensing investments, as set out in the medium-term management plan, and enable the early provision of a new treatment option.